• ARCA EGFP mRNA: A Causal Assay Framework

  2026-09-10

  ARCA EGFP mRNA provides a direct fluorescence readout for dissecting delivery, intracellular release, and mammalian cell gene expression. This guide develops a causal assay framework for interpreting reporter signal and applying it to transfection optimization and lipid nanoparticle research.

• ARCA EGFP mRNA for Transfection Control

  2026-09-10

  ARCA EGFP mRNA provides a direct fluorescence readout for comparing delivery conditions, mammalian cell expression, and lipid nanoparticle performance. Its ARCA cap and optimized poly(A) tail support a practical, sensitive control workflow without requiring antibody staining or destructive endpoint assays.

• Ceapin-A7 Workflow for ATF6α ER Stress Studies

  2026-09-09

  Ceapin-A7 provides a branch-resolved way to examine ATF6α signaling without treating the unfolded protein response as a single pathway. This workflow shows how to pair ATF6α pathway inhibition with the PERK–JAK1–STAT3–pyroptosis model in nucleus pulposus cells while preserving clear controls, practical assay readouts, and troubleshooting logic.

• Wnt-C59: PORCN Inhibitor Workflow Guide

  2026-09-09

  Wnt-C59 enables upstream control of Wnt ligand secretion for reporter, cholangiocarcinoma, and exosome-focused experiments. This guide pairs practical dosing and assay design with troubleshooting strategies that distinguish PORCN-dependent effects from downstream pathway or delivery artifacts.

• Afatinib in Gastric Cancer Assembloids

  2026-09-08

  Afatinib, also known as BIBW 2992, provides an irreversible ErbB-family perturbation strategy for patient-derived gastric cancer assembloids. This workflow connects EGFR, HER2, and HER4 pathway readouts with matched stromal biology to expose response changes that may be missed in tumor-only organoids.

• Tetrandrine: From Calcium Signaling to Translation

  2026-09-08

  A translational framework for using Tetrandrine as a mechanistic perturbation tool in calcium signaling, inflammation, neuroscience, and cancer biology research—while distinguishing established pharmacology from computational hypotheses.

• SGC-CBP30 and LUAD Enhancer Biology

  2026-09-07

  Super-enhancer hijacking links TGF-β/SMAD3 signaling with CBP/P300-dependent transcription in early-stage lung adenocarcinoma. This article positions SGC-CBP30 as a selective mechanistic probe for testing that axis while distinguishing published evidence from translational hypotheses and providing a practical experimental framework.

• Wnt-C59: Practical PORCN Inhibition Guide

  2026-09-07

  This scenario-based guide explains how Wnt-C59 (SKU A8685) can support controlled Wnt secretion studies, cell viability assays, and cholangiocarcinoma research. It covers mechanism, solvent compatibility, protocol design, interpretation, and practical product-selection criteria.

• Sulfaphenazole Restores Vascular Function in Diabetes

  2026-09-05

  The reference study identified CYP2C-derived oxidative stress as a contributor to impaired endothelium-dependent vasodilation in db/db diabetic mice. Sulfaphenazole treatment reduced plasma 8-isoprostane, increased nitric oxide bioavailability, and restored acetylcholine-mediated vascular relaxation without lowering glucose, linking CYP inhibition to endothelial protection rather than metabolic control.

• PP 3: A Rigorous Control for Redox–Src Studies

  2026-09-04

  1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is more than a nominal inactive analog: PP 3 helps separate Src-dependent effects from parallel redox and calcium signals. This article translates recent vascular findings into a practical control strategy for reproducible kinase assays.

• Targeted NAC Nanoparticles Suppress OA Ferroptosis

  2026-09-04

  A 2025 Small Science study developed chondroitin sulfate-modified PLGA nanoparticles to deliver N-acetylcysteine directly to chondrocytes and counter osteoarthritis-associated oxidative injury. The platform improved glutathione maintenance, preserved mitochondrial function, inhibited GPX4-linked ferroptosis, and reduced cartilage damage in a murine model more effectively than free NAC or nontargeted nanoparticles.

• HA-LNP PTEN mRNA for Transdermal Melanoma Therapy

  2026-09-03

  A 2026 Journal of Controlled Release study developed hyaluronate-conjugated lipid nanoparticles containing PTEN mRNA for topical delivery into melanoma-bearing skin. The HA-DMG formulation combined skin penetration, CD44-associated targeting, transient PTEN restoration, immunogenic cell death, and antitumor immune activation in preclinical models.

• Tamsulosin: Bench Protocols for Smooth Muscle Research

  2026-09-03

  Tamsulosin offers a practical way to connect selective α1A-receptor antagonism with measurable changes in smooth muscle tone, urinary flow, and ureteral function. This workflow-focused guide covers solvent handling, receptor and tissue assays, translational endpoints, and troubleshooting for reproducible urological research.

• MK0787 vs Cefoperazone: Comparative β-Lactam Activity

  2026-09-02

  Cullmann and colleagues evaluated N-formimidoyl thienamycin (MK0787) against a broad panel of resistant clinical isolates and compared its activity with cefoperazone and other contemporary β-lactams. The study’s central contribution was to connect comparative MIC results with bactericidal behavior and apparent independence from β-lactamase production, offering a useful framework for interpreting antibacterial spectrum and resistance phenotypes.

• Ziprasidone HCl: From Assay Signal to Data Quality

  2026-09-02

  Ziprasidone hydrochloride is more than a receptor pharmacology tool: its GOT1 activity and impurity profile directly shape translational assay quality. This article connects mechanism, analytical characterization, and practical study design for more defensible neuroscience and oncology research.

8502 records 1/567 page Next 12345 下5页 Last page